Lutris

Lutris Pharma is a clinical-stage biopharmaceutical company focused on improving the efficacy of cancer treatments and quality of life for patients receiving EGFR (epidermal growth factor receptor) inhibitors or radiotherapy, where skin toxicity often leads to reduced compliance with anticancer therapies. The company aims to provide new topical treatments to alleviate these side effects. Lutris Pharma's lead asset, LUT014, is a topical B-Raf inhibitor—a proprietary, first-in-class small molecule drug—currently in Phase 2 clinical trials for EGFR inhibitor-induced acneiform lesions in patients with metastatic colorectal cancer, as well as in a Phase 1/2 study for the treatment of radiodermatitis.